KEIO UNIVERSITY

Heart failure causes 13% of global deaths, with half of patients dying within 5 years. Despite 20 years of clinical trials, no cell-based therapies have been approved, though some show safety and benefits. The development of current therapies took nearly four decades, suggesting hope for future cell therapies. Ongoing trials explore new cell types, delivery methods, and products to improve heart failure treatment.

Keio University's Sara Horie and colleagues analyzed cancer driver alterations using genomic data from Japanese and international cohorts, revealing significant genomic differences between Asian and white populations, which have implications for molecularly targeted therapies.

New research identifies 18 bacterial strains that combat antibiotic-resistant Enterobacteriaceae, potentially leading to non-antibiotic therapies and biomarkers for treating gastrointestinal disorders.

A study explores how quantum optimization and QML can improve clinical trial design, site selection, and cohort identification, leveraging quantum algorithms to handle complex data. Despite hardware limitations, hybrid quantum-classical approaches are seen as the most viable option currently. Quantum computing promises to enhance trial simulations, site selection, and cohort identification, potentially accelerating trial timelines and improving efficiency.

AI and big data are revolutionizing drug development, significantly reducing costs and time by identifying potential drug targets, optimizing compound selection, and simulating clinical trials, promising more effective medicines for patients.